Release Date: February 28, 2017
Expiration Date: February 28, 2018
Media: Internet - based
This activity features an expert presentation that illustrates approaches to choosing initial therapy for patients with advanced non–small cell lung cancers (NSCLCs) and mutations in the epidermal growth factor receptor (EGFR) gene, how to navigate the nuances regarding the evaluation of acquired resistance, newer approaches to molecular testing, choosing subsequent approaches to therapy, and managing patients with central nervous system metastases. The goal of this activity is to help physicians and nurses synthesize recent data sets on newly available and late-stage investigational strategies to manage their patients with EGFR-mutated, advanced NSCLCs and to place new evidence in its proper context for physicians and nurses engaged in the treatment/management of patients with these tumors.
Instructions for This Activity and Receiving Credit
This educational activity is directed toward medical oncologists who treat patients with lung cancers. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of cancer are invited to participate.
At the conclusion of this activity, participants should be better prepared to:
- Detail evidence that underlies the application of optimized frontline strategies to manage EGFR-mutated, advanced non–small cell lung cancers (NSCLCs)
- Describe methods to optimize EGFR subtyping and emerging technologies that can practically facilitate tumor testing and overcome inherent challenges to optimized testing in community settings where advanced NSCLCs are managed
- Explain how to optimize the timing of clinical interventions in the relapsed, advanced NSCLC setting and the trial evidence that informs decision making to treat patients with EGFR-TKI resistance
- Address treatment-related toxicities and methods to optimize the management of central nervous system metastases in the care of patients with advanced NSCLCs.
Faculty, Staff, and Planners' Disclosures
Benjamin Levy, MD Associate Professor/Clinical Director, Medical Oncology
Johns Hopkins Medicine
Johns Hopkins Sidney Kimmel Cancer Center
Disclosure: Consultant: AstraZeneca, Celgene, Merck, Pfizer, Bristol-Myers Squibb, Eli Lilly, Genentech; Speakers Bureau: Genentech
Disclosure Policy and Resolution of Conflicts of Interest (COI)
It is the policy of PER® to ensure the fair balance, independence, objectivity, and scientific objectivity in all our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
Staff and Planners’ Disclosures
The staff of Physicians' Education Resource®, LLC, have no relevant financial relationships with commercial interests to disclose.
Off-Label Disclosure and Disclaimer
This CME/CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty member and does not reflect those of PER® or any of the companies that provided commercial support for this activity.
CME Provider Contact Information
Physicians’ Education Resource®, LLC
2 Clarke Drive
Cranbury, NJ 08512
Hardware And Software Requirements
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)
Minimum System Requirements (Windows)
- A Pentium-based PC or compatible computer
- At least 64MB of RAM
- Windows 95/98/NT/ME/2000/XP/Vista system software
- Screen resolution of 1024 x 786 or larger recommended
- PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
Minimum System Requirements (Mac OS)